Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02172794
Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02172417
Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 10773 - low doseDrug: BI 10773 - high doseDrug: BI 10773 - medium dose
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02172235
Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4700
- Registration Number
- NCT02172495
Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Tersigan®
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 161
- Registration Number
- NCT02172430
HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: Placebo capsule administered via the HandiHaler®Device: Ipratropium metered dose inhaler (MDI)
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 160
- Registration Number
- NCT02172404
Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT02172443
Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
Phase 3
Completed
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 315
- Registration Number
- NCT02172573
The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy Subjects
Phase 1
Completed
- Conditions
- Renal Insufficiency
- Interventions
- Drug: Tiotropium, solution ampoules
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02172339
Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1536
- Registration Number
- NCT02172521
© Copyright 2025. All Rights Reserved by MedPath